1. Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting

2. Cancer-Treatment-Induced Bone Loss (CTIBL)

3. Clodronate and Bone Mineral Density (Hip)

4. Bone Mineral Density Substudy --ABCSG-12: Effect of Zoledronic Acid Percent Change, Lumbar Spine

5. Denosumab for CTIBL (Lumbar Spine)

6. Metastatic Niches in Bone Marrow

7. Differential Impact of Menopausal Status

8. The "Low Estrogen" Hypothesis

9. Adjuvant Bisphosphonate Treatment Breast Cancer Recurrence-Postmenopause*

10. Conclusions: EBCTCG Meta-Analysis

11. ABCSG-12 Trial Design

12. Adjuvant Denosumab in Breast Cancer (ABCSG-18, Phase 3) Primary Endpoint, First Clinical Fracture

13. Adjuvant Denosumab in Breast Cancer (ABCSG-18 Subgroup) Tumor Size > 2 cm

14. Bone-Targeting Therapy in Adjuvant Breast Cancer Setting Clinical Conclusions

16. References

17. References (cont)

18. References (cont)

19. Abbreviations